HNSCC collection

161 abstracts

Abstract JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC) Congress:ESMO 2024, Search all connections
Abstract Petosemtamab plus pembrolizumab vs. pembrolizumab alone for first-line (1L) treatment of recurrent/metastatic (r/m) PD-L1â€“positive head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial Congress:ESMO 2024, Search all connections
Abstract Petosemtamab compared with investigatorâ€™s choice monotherapy in previously treated patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial Congress:ESMO 2024, Search all connections
Abstract A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC) Congress:ESMO 2024, Search all connections
Abstract Phase II multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of HB-200 in patients with detectable TTMV-HPV DNA after definitive treatment for HPV16 + HNSCC Congress:ESMO 2024, Search all connections
Abstract Phase II TROPHY-IO-HN study of pembrolizumab Â±sacituzumab govitecan in first-line recurrent /metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients Congress:ESMO 2024, Search all connections
Abstract Longer OS and RFS for CD3high/PD-L1+ head and neck squamous cell carcinoma (HNSCC) patients Congress:ESMO 2024, Search all connections
Abstract Association of genomic landscape and plasma protein dynamic changes with clinical outcome in patients with R/M HNSCC treated with pembrolizumab with nab-paclitaxel and platinum Congress:ESMO 2024, Search all connections
Abstract Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005 Congress:ESMO 2024, Search all connections
Abstract Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) Congress:ESMO 2024, Search all connections
Abstract Cetuximab with dalpicilib in patients with HPV-negative, anti-PD-1 resistant R/M HNSCC Congress:ESMO 2024, Search all connections
Abstract VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) Congress:ESMO 2024, Search all connections
Abstract Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC Congress:ESMO 2024, Search all connections
Abstract Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC) Congress:ESMO 2024, Search all connections
Abstract A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) Congress:ESMO 2024, Search all connections
Abstract Safety and efficacy of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase Ib/II study Congress:ESMO 2024, Search all connections
Abstract Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study Congress:ESMO 2024, Search all connections
Abstract POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) Congress:ESMO 2024, Search all connections
Abstract Clinical/biomarker data for neoadjuvant tislelizumab (TIS) plus chemotherapy (Chemo) in resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A single-arm, phase II trial Congress:ESMO 2024, Search all connections
Abstract Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC) Congress:ESMO 2024, Search all connections
Abstract Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study Congress:ESMO 2024, Search all connections
Abstract Cachexia in head and neck squamous cell carcinoma (HNSCC) patients (pts) after cisplatin-based chemoradiation (CRT): A cross-sectional study. Congress:ASCO 2019, Search all connections
Abstract Evolution of standard of care therapies used for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A real-world analysis of patient health records from 2016 to 2019. Congress:ASCO 2019, Search all connections
Abstract Incidence of severe late toxicities of head and neck squamous cell cancer (HNSCC) treatment in the era of intensity modulated radiotherapy (IMRT). Congress:ASCO 2019, Search all connections
Abstract Factors associated with non-completion of radiation therapy (RT) or radiochemotherapy (RTCT) in head and neck squamous cell carcinoma (HNSCC): A prospective study. Congress:ASCO 2019, Search all connections
Abstract Translating transcriptome to immunophenotype in head and neck squamous cell carcinoma (HNSCC) to identify pathways promoting T-cell infiltration. Congress:ASCO 2019, Search all connections
Abstract Synchronous esophageal cancer impact on survival of head and neck squamous cell carcinoma (HNSCC) patients. Congress:ASCO 2019, Search all connections
Abstract Biomarkers of resistance to cetuximab in head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2019, Search all connections
Abstract ELAN-ONCOVAL (Elderly Head and Neck Cancer-Oncology Evaluation) study: Evaluation of the G8 screening tool and the ELAN geriatric evaluation (EGE) for elderly patients (pts) with head and neck squamous cell carcinomas (HNSCC). Congress:ASCO 2019, Search all connections
Abstract Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy. Congress:ASCO 2019, Search all connections
Abstract A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physician’s choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC). Congress:ASCO 2019, Search all connections
Abstract Long-term survival of adjuvant high-dose (HDC) vs weekly cisplatin (WC) for human papilloma-virus (HPV) and non-HPV head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2019, Search all connections
Abstract Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504. Congress:ASCO 2019, Search all connections
Abstract Hafnium oxide nanoparticles NBTXR3 activated by radiotherapy as a new therapeutic option for elderly/frail HNSCC patients. Congress:ASCO 2019, Search all connections
Abstract Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2019, Search all connections
Abstract Prognostic impact of baseline circulating tumor cells (CTCs) detected by the isolation by size of epithelial tumor cells (ISET) in locally advanced head and neck squamous cell carcinoma (LAHNSCC): Results of a prospective study. Congress:ASCO 2019, Search all connections
Abstract Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142). Congress:ASCO 2019, Search all connections
Abstract Connective tissue growth factor (CTGF) methylation status is associated with prognosis of patients with head and neck squamous cell carcinoma (HNSCC) treated with radiochemotherapy (RCHT): A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Congress:ASCO 2019, Search all connections
Abstract Association between human papillomavirus (HPV) status and duration of response of anti-programmed cell death protein-1 (PD-1) inhibitors in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2019, Search all connections
Abstract Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2019, Search all connections
Abstract Clinical implications of hyperprogression with immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2019, Search all connections
Abstract CDX3379-04: Phase II evaluation of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2019, Search all connections
Abstract Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state. Congress:ASCO 2019, Search all connections
Abstract Metformin treatment of locally advanced head and neck squamous cell carcinoma (LAHNSCC) patients induces an anti-tumorigenic immune response. Congress:ASCO 2019, Search all connections
Abstract Preclinical efficacy of copanlisib in cetuximab sensitive and resistant tumors of HNSCC. Congress:ASCO 2019, Search all connections
Abstract An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis. Congress:ASCO 2019, Search all connections
Abstract Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI). Congress:ASCO 2019, Search all connections
Abstract Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial. Congress:ASCO 2019, Search all connections
Abstract A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2019, Search all connections
Abstract Discordant treatment response in primary tumors and lymph node metastases after four weeks of preoperative PD-1 blockade in head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2019, Search all connections
Abstract Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC). Congress:ASCO 2019, Search all connections
Abstract EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Congress:ASCO 2019, Search all connections
Abstract NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high risk head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2019, Search all connections
Abstract TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Congress:ASCO 2019, Search all connections
Abstract Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Congress:ASCO 2019, Search all connections
Abstract Interim analysis for window of opportunity trial of single dose preoperative durvalumab (D) with or without tremelimumab (T) for operable head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2021, Search all connections
Abstract Factors associated with hospitalization in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with definitive chemoradiation (CRT). Congress:ASCO 2021, Search all connections
Abstract Development and validation of an unfolded protein response-related gene signature to predict overall survival in HNSCC. Congress:ASCO 2021, Search all connections
Abstract Genomic characterization of p16+ compared to p16- HNSCC patients treated with immune checkpoint inhibitors and overall survival. Congress:ASCO 2021, Search all connections
Abstract Network meta-analysis (NMA) of pembrolizumab for first-line (1L) treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2021, Search all connections
Abstract Frequency of DNA repair gene mutations and impact on prognosis in HNSCC. Congress:ASCO 2021, Search all connections
Abstract Cost-effectiveness (CE) analysis of pembrolizumab as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States (US). Congress:ASCO 2021, Search all connections
Abstract Circulating tumor cells demonstrate a positive biomarker in head and neck squamous cell carcinoma (HNSCC) in tobacco consuming population of Bangladesh. Congress:ASCO 2021, Search all connections
Abstract MVX-ONCO-1 in advanced refractory cancers: Safety, feasibility, and preliminary efficacy results from all HNSCC patients treated in two ongoing clinical trials. Congress:ASCO 2021, Search all connections
Abstract Phase II multicenter randomized trial to assess the efficacy and safety of first line nivolumab in combination with paclitaxel in subjects with R/M HNSCC unable for cisplatin-based chemotherapy (NIVOTAX): A TTCC study. Congress:ASCO 2021, Search all connections
Abstract Pathologic and radiographic responses in a window of opportunity for durvalumab plus metformin trial for squamous cell carcinoma of the head and neck (HNSCC). Congress:ASCO 2021, Search all connections
Abstract Quantitative immunofluorescence and mRNA analysis of immune-related biomarker groups in matched paired tumor samples from OPHELIA window study in head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2021, Search all connections
Abstract Impact of COVID19 pandemic on treatment outcome of locally-advanced head and neck squamous cell carcinoma (LA-HNSCC): IMPACCT study. Congress:ASCO 2021, Search all connections
Abstract Impact of comprehensive geriatric assesment (CGA) in the treatment decision and outcome of older patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Congress:ASCO 2021, Search all connections
Abstract Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients. Congress:ASCO 2021, Search all connections
Abstract Evaluation of radiomics as a predictor of tumor hypoxia and response to anti-PD-1 mab treatment (IO) in recurrent/metastatic HNSCC patients (R/M). Congress:ASCO 2021, Search all connections
Abstract Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232. Congress:ASCO 2021, Search all connections
Abstract Priming immunotherapy with radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC): Interim analysis of phase II clinical trial. Congress:ASCO 2021, Search all connections
Abstract Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2021, Search all connections
Abstract Efficacy of concurrent cetuximab (CTX) and nivolumab (NIVO) in previously untreated recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2021, Search all connections
Abstract Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2021, Search all connections
Abstract Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T-cell infiltration. Congress:ASCO 2021, Search all connections
Abstract Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2021, Search all connections
Abstract PEP503 (NBTXR3), a radioenhancer, in combination with concurrent chemoradiation (CCRT) in locally advanced or recurrent head and neck squamous cell carcinoma (HNSCC): Dose-finding of a phase 1b/2 trial. Congress:ASCO 2022, Search all connections
Abstract A feasibility study of EMF(erlotinib+methotrexate+5-fluorouracil) regimen in recurrent head and neck squamous cell carcinoma (HNSCC) and role of circulating tumour cells(CTCs) in assessment of outcomes. Congress:ASCO 2022, Search all connections
Abstract Real-world time on treatment analysis of pembrolizumab treated recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC) patients stratified by ECOG PS in the United States. Congress:ASCO 2022, Search all connections
Abstract Centrally determined PD-L1 among non-eligible for cisplatin-based chemotherapy recurrent/metastatic head and neck patients (R/M HNSCC pts): Pathology outcomes from the NIVOTAX trial. Congress:ASCO 2022, Search all connections
Abstract A pilot study of neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab in patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2022, Search all connections
Abstract Neoadjuvant nivolumab with or without IDO inhibitor in head and neck squamous cell carcinoma (HNSCC): Final pathologic and clinical outcomes. Congress:ASCO 2022, Search all connections
Abstract Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC): Updated results with high dimensional profiling of circulating immune cells. Congress:ASCO 2022, Search all connections
Abstract Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial. Congress:ASCO 2022, Search all connections
Abstract Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC). Congress:ASCO 2022, Search all connections
Abstract Gut microbiome/metabolome predicts response to immune checkpoint blockers (ICB) in patients with recurrent metastatic head and neck squamous cell cancer (RM HNSCC). Congress:ASCO 2022, Search all connections
Abstract Clinicopathologic characteristics of HRAS-mutant head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2022, Search all connections
Abstract The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). Congress:ASCO 2022, Search all connections
Abstract PDS0101, a novel type I interferon and CD8 T-cell activating immunotherapy, in combination with pembrolizumab in subjects with recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2022, Search all connections
Abstract CA209-9KY: Results of a phase II study of intensity modulated radiotherapy (IMRT) re-irradiation and concurrent/adjuvant nivolumab (nivo) in patients with loco-regionally recurrent or second primary (RSPT) head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2022, Search all connections
Abstract Preliminary safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): A phase Ib/II clinical trial. Congress:ASCO 2022, Search all connections
Abstract Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2022, Search all connections
Abstract Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC. Congress:ASCO 2022, Search all connections
Abstract A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). Congress:ASCO 2022, Search all connections
Abstract The smart options of induction therapy for locally advanced betel-nuts related HNSCC in Taiwan. Organization:Department of Oncolo...,National Taiwan Univ...,Yunlin,Drug:cetuximab, Search all connections
Abstract Treatment patterns and clinical outcomes of newly diagnosed locally advanced head and neck squamous cell carcinoma (LA HNSCC): A retrospective cohort analysis of national real-world data in England. Organization:Merck & Co., Inc.,Comprehensive Cancer...,Merck Sharp & Dohme ...,Drug:platinum-based chemo...,Target:DNA,Congress:ASCO 2023, Search all connections
Abstract Efficacy and safety of induction chemotherapy with docetaxel + cisplatin in selected groups of patients with HNSCC. Organization:Pavlov University,Saint-Petersburg, Ru...,Saint-Petersburg Sta...,Drug:docetaxel,Cisplatin, Search all connections
Abstract Association of patient and tumor characteristics with outcomes in young patients with head and neck squamous cell carcinoma (HNSCC). Organization:University of Pittsb...,University of Pittsb...,University of Pittsb..., Search all connections
Abstract Patients characteristics, treatment patterns and clinical outcomes in patients with head and neck squamous cell carcinoma (aHNSCC) receiving immunotherapy in advanced setting: Retrospective cohort analysis of real-world data in Spain. Organization:Servicio de Oncologí...,Hospital Universitar...,Jaén, Spain,Drug:nivolumab,pembrolizumab,platinum chemotherap...,Target:PD-1, Search all connections
Abstract Clinical characterization of responders to first line (chemo)immunotherapy in platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC). Organization:Head and Neck Cancer...,Fondazione IRCCS Ist...,Department of Oncolo...,Drug:immunotherapy,Cisplatin, Search all connections
Abstract Nimotuzumab in combination with intensity modulated radiotherapy improve survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A multicenter-based real-world study. Clinical trial:BPL-Nimo-SCCHN-RWS-1,Organization:Department of Radiat...,Sichuan Cancer hospi...,Department of Oral a..., Search all connections
Abstract Prospective evaluation of factors associated with acceptance of feeding tube (FT) placement and clinical outcomes during radiation therapy (RT) or radiochemotherapy (RTCT) for head and neck squamous cell carcinoma (HNSCC). Organization:Department of Medica...,Centre Henri Becquer...,Centre H. Becquerel,Drug:Varlilumab,RTCT,FTD/TPI,Target:chemotherapy, Search all connections
Abstract Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial. Organization:Washington Universit...,Natco Pharma,NATCO Pharma Limited,Drug:pembrolizumab,nivolumab,cetuximab, Search all connections
Abstract A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC. Clinical trial:GS-US-548-5916,Organization:Stanford Cancer Cent...,Portuguese Oncology ...,The Kinghorn Cancer ..., Search all connections
Abstract Palbociclib + cetuximab versus cetuximab in patients with CDKN2A-altered, anti-PD-1 resistant, HPV-negative head and neck squamous cell carcinoma (HNSCC): A phase 3 trial. Clinical trial:202108203,Organization:Washington Universit...,Washington Universit...,Drug:palbociclib,cetuximab,Target:EGFR-TKI sensitizing...,CDK6,CDK4 & 6, Search all connections
Abstract Combined pulsed radiotherapy (QUAD shot regimen) with immune checkpoint inhibition (ICI) to enhance immune response for LAHNSCC in patients considered ineligible for curative intent therapy. Organization:Grandview Cancer Cen...,Helen F. Graham Canc...,Thomas Jefferson Uni...,Drug:pembrolizumab,cemiplimab,Target:PD-1, Search all connections
Abstract Development of CT-based radiomic model to predict 5-year progression-free survival (PFS) in locally advanced head and neck squamous cell carcinoma (LAHNSCC) treated with definitive chemoradiation. Organization:INCLIVA Biomedical R...,QUIBIM SL,Quibim S.L.,Drug:Cisplatin,Congress:ASCO 2023, Search all connections
Abstract Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Organization:NeoGenomics Ltd,Cancer Genomics Prog...,Laboratory Medicine ..., Search all connections
Abstract Introduction of E-Score: A gene expression score to characterize immunogenic versus oncogenic HPV expression in HNSCC. Organization:University of Michig...,Georgetown Universit...,Congress:ASCO 2023, Search all connections
Abstract Single-cell RNA and T cell receptor (TCR) sequencing in patients with HPV-positive head and neck squamous cell carcinoma (HNSCC) after induction CTLA4 and PD-1 immune checkpoint blockade (ICB). Clinical trial:2018-0381,Organization:The University of Te...,Rice University,Drug:CTLA-4,PD-1 inhibitors,Target:CTLA-4,PD-1,Congress:ASCO 2023, Search all connections
Abstract Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N). Clinical trial:MCC-19178,Organization:Moffitt Cancer Cente...,Broad Institute of M...,IBM Watson Health, Search all connections
Abstract Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling. Organization:mProbe Inc.,Stanford University ...,Drug:mFOLFOXIRI,topotecan,doxorubicin, Search all connections
Abstract Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients. Clinical trial:UCCI-HN-19-03,Organization:University of Cincin...,Mid-Florida Hematolo...,University of Cincin...,Drug:niraparib, Search all connections
Abstract Safety and efficacy of time restricted eating (TRE) in improving response to immunotherapy in head and neck cancer (HNSCC) patients. Organization:H. Lee Moffitt Cance...,Duke Medical Center,Moffitt Cancer Cente..., Search all connections
Abstract Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial. Organization:Centre Léon Bérard,Centre de Lutte Cont...,GINECO-Centre Jean P...,Drug:abemaciclib, Search all connections
Abstract Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC). Organization:University of Pennsy...,Stanford Cancer Cent...,Drug:pembrolizumab,platinum-based chemo...,5-FU, Search all connections
Abstract Evaluation of small extracellular vesicles as biomarkers of efficacy with anti-PD-1 mAb therapy in patients with recurrent/metastatic HNSCC. Organization:UPMC Hillman Cancer ...,University of Pittsb...,University of Pittsb...,Drug:anti-PD-1 mAb,Target:PD-1,Congress:ASCO 2023, Search all connections
Abstract Evaluation of ICI sensitivity for pembrolizumab in combination with anti-platelet therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). Clinical trial:102727,Organization:The Pelotonia Instit...,The Ohio State Unive...,Columbus, OH, Search all connections
Abstract Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC. Clinical trial:1100,Organization:H. Lee Moffitt Cance...,Banner MD Anderson C...,Moffitt Cancer Cente...,Drug:NBTXR3, Search all connections
Abstract Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). Organization:Shanghai East Hospit...,Union Hospital,Cancer Hospital of t..., Search all connections
Abstract To test, or not to test, that is the question: A real-world analysis of PD-L1 expression testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Organization:Merck & Co., Inc.,Dana-Farber Cancer I...,Drug:pembrolizumab,platinum-based chemo...,5-FU,Target:PD-1,thymidine phosphoryl...,thymidylate synthase, Search all connections
Abstract Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial. Clinical trial:202105128,Organization:Washington Universit...,Washington Universit...,Drug:Abraxane,nivolumab,Target:PD-1,EGFR-TKI sensitizing...,RAS/BRAF, Search all connections
Abstract Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial. Clinical trial:202011174,Organization:Washington Universit...,Washington Universit...,Drug:tazemetostat,pembrolizumab,Target:EZH2,PD-1,Congress:ASCO 2023, Search all connections
Abstract Association of neutrophil-lymphocyte ratio (NLR) with clinical outcomes in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with combination of cetuximab and nivolumab (C+N). Clinical trial:MCC-19178,Organization:Moffitt Cancer Cente...,The Ohio State Unive...,Emory University Sch..., Search all connections
Abstract DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab plus tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative head and neck squamous cell carcinoma (LA-HNSCC). Clinical trial:DURTRE-RAD,Organization:Charité-Universitäts...,Humboldt-Universität...,Berlin Institute of ..., Search all connections
Abstract Dynamic change of immune phenotype assessed by artificial intelligence (AI)-powered analysis of tumor-infiltrating lymphocytes (TILs) during neoadjuvant durvalumab with or without tremelimumab (D+/-T) in head and neck squamous cell carcinoma (HNSCC). Clinical trial:4-2018-0787,Organization:Yonsei Cancer Center...,Lunit Inc.,Heavy Ion Research I...,Drug:durvalumab,tremelimumab,Target:CTLA-4,PD-L1, Search all connections
Abstract Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC). Clinical trial:HCC 18-139,Organization:University of Pittsb...,University of Pittsb...,University of Pittsb..., Search all connections
Abstract Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC). Clinical trial:PDS0101-HNC-201,Organization:PDS Biotechnology,Merck & Co., Inc.,Lineberger Comprehen...,Drug:PDS0101, Search all connections
Abstract Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial. Clinical trial:201802162,Organization:Washington Universit...,Washington Universit...,Department of Surger...,Drug:palbociclib,cetuximab, Search all connections
Abstract Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC). Clinical trial:20-445,Organization:Memorial Sloan Kette...,Drug:cemiplimab,Cisplatin,carboplatin,Target:PD-1, Search all connections
Abstract Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial. Clinical trial:202104144,Organization:Washington Universit...,Washington Universit...,Drug:olaparib,pembrolizumab,carboplatin,Target:PD-1,PARP, Search all connections
Abstract Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay. Drug:cetuximab,pembrolizumab,nivolumab,Target:PD-1, Search all connections
Abstract Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): A retrospective study in 39 patients (pts). Drug:platinum-based chemo...,5FU,PMB,Target:thymidylate synthase,PMB,CpG-rich Domain, Search all connections
Abstract Time restricted eating (TRE) and immunotherapy outcomes in head and neck squamous cell carcinoma (HNSCC) via modulation of microbial butyrate and tryptophan metabolic pathways. Drug:tremelimumab,Target:hydroxy indole aceti...,butyric acid,butyrate kinase,Organization:Duke Cancer Institut...,Duke Medical Center,Duke University Scho..., Search all connections
Abstract Comparative efficacy of pembrolizumab with carboplatin and paclitaxel as first-line (1L) therapy in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A network meta-analysis (NMA) with matching-adjusted indirect comparison (MAIC). Drug:KNB10,pembrolizumab,platinum-based chemo..., Search all connections
Abstract Impact of comorbidity on outcome and treatment choice in patients with head and neck squamous cell carcinoma (HNSCC). Organization:IRCCS-Biostatistical...,Otorinolaringoyathry...,UniCamillus Internat...,Congress:ASCO 2024, Search all connections
Abstract Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial. Drug:cetuximab,PD-1 inhibitors,camrelizumab,Target:PD-1,tubulin,EGFR-TKI sensitizing..., Search all connections
Abstract Survival outcomes of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with platinum-based chemotherapy plus paclitaxel after anti-PD-1 monotherapy. Drug:Cisplatin,carboplatin,paclitaxel,Target:paclitaxel,carboplatin,PD-1, Search all connections
Abstract Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study. Drug:Petosemtamab,pembrolizumab,Target:Programmed death rec...,LGR5,EGFR-TKI sensitizing...,Organization:Vall d'Hebron Hospit...,Sarah Cannon Researc...,Vall d'Hebron Hospit..., Search all connections
Abstract Feasibility study of a personalized tumor membrane vesicle vaccine immunotherapy for head and neck squamous cell carcinoma (HNSCC). Drug:GPI-B7-1,GPI-IL-12,anti-PD1,Target:CTLA-4,PD-1,GPI-B7-1,Organization:Metaclipse Therapeut..., Search all connections
Abstract Real-world treatment patterns and overall survival (OS) in locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) in the U.S. Organization:Analysis Group, Inc.,Merck & Co., Inc.,Department of Medica...,Congress:ASCO 2024, Search all connections
Abstract eVOLVE-HNSCC: A global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT). Drug:pembrolizumab,nivolumab,volrustomig,Target:CTLA-4,PD-1,Organization:Head and Neck Medica...,Department of Oncolo...,Clinical trial:D798EC00001, Search all connections
Abstract PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC). Drug:Danvatirsen,durvalumab,pembrolizumab,Target:STAT3,PD-L1,PD-1,Organization:Stathmi, Inc.,Clinical trial:FLM-6774-201, Search all connections
Abstract Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): MERIDIAN study. Drug:rilvegostomig,AZD2936,TIGIT,Target:PD-1,TIGIT,Organization:NeoGenomics Ltd,Congress:ASCO 2024, Search all connections
Abstract A phase III randomized, open-label study to establish the superiority of triple oral metronomic therapy (OMCT) used in addition to chemotherapy regimen (paclitaxel + carboplatin) over chemotherapy alone for the treatment of advanced unresectable head and neck cancer squamous cell cancer (HNSCC). Drug:Erlotinib,Celecoxib,methotrexate,Target:dihydrofolate reduct...,COX-2,EGFR-TKI sensitizing..., Search all connections
Abstract A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC). Drug:anti-PD1,TBio-4101,pembrolizumab,Target:tumor-reactive T cel...,PD-1,endogenous neoantige..., Search all connections
Abstract Recent safety and efficacy findings from a phase 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma (HNSCC). Drug:ASP-1929,cetuximab,IRDye 700DX,Target:PD-1,EGFR-TKI sensitizing...,Organization:Thomas Jefferson Uni...,University of Miami ..., Search all connections
Abstract Relationship between infiltration of tissue-resident memory T cells (TRM) in head and neck squamous cell carcinoma (HNSCC) tissue and localization and age. Organization:Ulm University Medic...,CRUK and NIHR Experi...,Head & Neck Surgery,Congress:ASCO 2024, Search all connections
Abstract Can TTMV clearance predict recurrence in HPV HNSCC? Organization:Hematology and Medic...,Icahn School of Medi...,Mount Sinai Medical ...,Clinical trial:STUDY-21-01683, Search all connections
Abstract A phase II trial of reirradiation combined with pembrolizumab in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (HNSCC). Organization:UPMC Hillman Cancer ...,University of Maryla...,Congress:ASCO 2024, Search all connections
Abstract Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100. Drug:NBTXR3,nivolumab,pembrolizumab,Target:hafnium oxide nanopa...,PD-1,Programmed death rec...,Organization:H. Lee Moffitt Cance...,Banner MD Anderson C..., Search all connections
Abstract A phase 1 study of fianlimab (anti–LAG-3) in combination with cemiplimab (anti–PD-1) in patients with advanced HNSCC. Drug:fianlimab,cemiplimab,Target:PD-1,LAG-3,Organization:Zuckerberg Cancer Ce...,Tallaght University ...,Clinical trial:R3767-ONC-1613,Congress:ASCO 2024, Search all connections
Abstract Clinical, molecular, and immunologic profiling of brain metastases (BM) in head and neck squamous cell carcinoma (HNSCC). Organization:Phase Genomics, Inc.,Congress:ASCO 2024, Search all connections
Abstract Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study. Drug:pembrolizumab,Nab-Paclitaxel,Cisplatin,Target:Programmed cell deat...,microtubules,DNA, Search all connections
Abstract Off-label use of checkpoint inhibitor (CPI) monotherapy in PD-L1–negative or unknown recurrent/metastatic head and neck cancer (R/M HNSCC). Organization:Hospital of the Univ...,University of Pennsy...,Department of Biosta...,Congress:ASCO 2024, Search all connections
Abstract End of life (EOL) care in head and neck squamous cell carcinoma (HNSCC) compared to other solid tumors (OST) in Washington (WA) State. Organization:Fred Hutchinson Canc...,Seattle Gummy Compan...,Wave Life Sciences, Search all connections
Abstract Personalized cell-free tumor DNA analysis for patients with HNSCC: Liquid biopsy for minimal residual disease detection in head and neck squamous cell carcinoma (LIONESS). Organization:The Bradfield Centre,NeoGenomics Laborato...,Congress:ASCO 2024, Search all connections
Abstract A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC). Organization:H. Lee Moffitt Cance...,Washington Universit...,University of Washin..., Search all connections
Abstract Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial. Organization:University of Chicag...,University of Chicag...,Department of Medici...,Product:Nivolumab,Clinical trial:IRB19-0162, Search all connections